JP2000504210A5 - - Google Patents

Download PDF

Info

Publication number
JP2000504210A5
JP2000504210A5 JP1997524551A JP52455197A JP2000504210A5 JP 2000504210 A5 JP2000504210 A5 JP 2000504210A5 JP 1997524551 A JP1997524551 A JP 1997524551A JP 52455197 A JP52455197 A JP 52455197A JP 2000504210 A5 JP2000504210 A5 JP 2000504210A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1997524551A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000504210A (ja
JP4037905B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1996/020718 external-priority patent/WO1997024440A1/en
Publication of JP2000504210A publication Critical patent/JP2000504210A/ja
Publication of JP2000504210A5 publication Critical patent/JP2000504210A5/ja
Application granted granted Critical
Publication of JP4037905B2 publication Critical patent/JP4037905B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP52455197A 1995-12-27 1996-12-19 半減期の長いobタンパク質誘導体 Expired - Lifetime JP4037905B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US57949495A 1995-12-27 1995-12-27
US08/579,494 1995-12-27
US66718496A 1996-06-20 1996-06-20
US08/667,184 1996-06-20
PCT/US1996/020718 WO1997024440A1 (en) 1995-12-27 1996-12-19 Ob protein derivatives having prolonged half-life

Publications (3)

Publication Number Publication Date
JP2000504210A JP2000504210A (ja) 2000-04-11
JP2000504210A5 true JP2000504210A5 (cg-RX-API-DMAC7.html) 2004-11-11
JP4037905B2 JP4037905B2 (ja) 2008-01-23

Family

ID=27077779

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52455197A Expired - Lifetime JP4037905B2 (ja) 1995-12-27 1996-12-19 半減期の長いobタンパク質誘導体

Country Status (14)

Country Link
EP (1) EP0870026B1 (cg-RX-API-DMAC7.html)
JP (1) JP4037905B2 (cg-RX-API-DMAC7.html)
CN (1) CN1154726C (cg-RX-API-DMAC7.html)
AT (1) ATE267255T1 (cg-RX-API-DMAC7.html)
AU (1) AU1520097A (cg-RX-API-DMAC7.html)
BR (1) BR9612359A (cg-RX-API-DMAC7.html)
CA (1) CA2238307A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ9802013A3 (cg-RX-API-DMAC7.html)
DE (1) DE69632546T2 (cg-RX-API-DMAC7.html)
IL (1) IL124831A0 (cg-RX-API-DMAC7.html)
MX (1) MX9804687A (cg-RX-API-DMAC7.html)
NZ (1) NZ326592A (cg-RX-API-DMAC7.html)
RU (1) RU2178307C2 (cg-RX-API-DMAC7.html)
WO (1) WO1997024440A1 (cg-RX-API-DMAC7.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
ES2093593T1 (es) * 1995-05-05 1997-01-01 Hoffmann La Roche Proteinas obesas (ob) recombinantes.
CA2236163A1 (en) * 1995-11-22 1997-05-29 Amgen Inc. Methods of increasing lean tissue mass using ob protein compositions
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
EP1835030A1 (en) * 1996-12-20 2007-09-19 Amgen, Inc. OB fusion protein compositions and methods
AU770897B2 (en) * 1996-12-20 2004-03-04 Amgen, Inc. OB fusion protein compositions and methods
AU7132798A (en) * 1997-04-17 1998-11-11 Amgen, Inc. Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods
AU2002300605B8 (en) * 1997-04-17 2006-02-09 Amgen Inc. Compositions Comprising Conjugates of Stable, Active, Human OB Protein with Antibody FC Chain and Methods
US6017876A (en) * 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
EP1489100B1 (en) 1997-12-08 2016-06-15 Merck Patent GmbH Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
ATE417068T1 (de) 1998-04-23 2008-12-15 Ajinomoto Kk Stoff mit antithrombotischer aktivität und verfahren zur bestimmung von glycokallidin
US6492138B1 (en) 1998-05-21 2002-12-10 Amgen Canada Inc. Polynucleotides encoding a novel SHC-binding protein
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001010912A1 (en) 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
AU2154401A (en) 1999-11-12 2001-05-30 Merck Patent Gmbh Erythropoietin forms with improved properties
US7091321B2 (en) 2000-02-11 2006-08-15 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of antibody-based fusion proteins
EP1294401B1 (en) 2000-06-29 2007-08-01 EMD Lexigen Research Center Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
AU2002252035A1 (en) 2001-02-21 2002-09-12 Surromed, Inc. Modified annexin proteins and methods for preventing thrombosis
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
CN1330664C (zh) 2001-03-07 2007-08-08 默克专利有限公司 用于含杂合同种型抗体部分的蛋白质的表达技术
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
CA2446087C (en) 2001-05-03 2013-06-18 Stephen D. Gillies Recombinant tumor specific antibody and use thereof
EP1454138B1 (en) 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
MXPA05006384A (es) 2002-12-17 2005-08-29 Merck Patent Gmbh Anticuerpo humanizado (h14.18) del anticuerpo 14.18 de raton enlazado a gd2 y su fusion con il-2.
KR20050086948A (ko) 2002-12-27 2005-08-30 디오벡스, 인코포레이티드 인슐린으로 인한 저혈당증을 예방하고 조절하기 위한조성물 및 방법
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
EP1682584B1 (en) * 2003-11-13 2013-04-17 Hanmi Science Co., Ltd. A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
PT1699822E (pt) 2003-12-30 2008-07-30 Merck Patent Gmbh Proteínas de fusão de il-7
BRPI0417916A (pt) 2003-12-31 2007-04-10 Merck Patent Gmbh proteìna de fusão de fc-eritropoietina com farmacocinética melhorada
US8420087B2 (en) 2004-01-05 2013-04-16 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
KR100639397B1 (ko) * 2004-03-18 2006-10-26 (주)에스제이바이오메드 항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물
US7589179B2 (en) 2004-12-09 2009-09-15 Merck Patent Gmbh IL-7 variants with reduced immunogenicity
US8227408B2 (en) 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
EP1972349A1 (en) * 2007-03-21 2008-09-24 Biocompatibles UK Limited GLP-1 fusion peptides conjugated to polymer(s), their production and use
JP5622720B2 (ja) 2008-05-21 2014-11-12 ニューロテスインコーポレイテッド 神経原繊維変化に関連する進行性認知障害の治療方法
JP2012508242A (ja) 2008-11-04 2012-04-05 ニコラオス テザプシディス 神経原線維のもつれ及びアミロイドβの蓄積に起因する進行性認知機能障害を治療するためのレプチン組成物及び方法
CN102405230A (zh) 2009-04-22 2012-04-04 默克专利有限公司 具有修饰的FcRn结合位点的抗体融合蛋白
CN104147596A (zh) * 2013-05-14 2014-11-19 李荣秀 生物药非共价结合聚合物延长治疗浓度的方法及用途
CN104524568B (zh) * 2015-01-08 2018-04-20 中国人民解放军第二军医大学 一种治疗肥胖症的药物组合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
ES2093593T1 (es) * 1995-05-05 1997-01-01 Hoffmann La Roche Proteinas obesas (ob) recombinantes.
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound

Similar Documents

Publication Publication Date Title
JP2000500033A5 (cg-RX-API-DMAC7.html)
JP2000500445A5 (cg-RX-API-DMAC7.html)
JP2000500440A5 (cg-RX-API-DMAC7.html)
JP2000502851A5 (cg-RX-API-DMAC7.html)
JP2000500145A5 (cg-RX-API-DMAC7.html)
JP2000500155A5 (cg-RX-API-DMAC7.html)
JP2000500406A5 (cg-RX-API-DMAC7.html)
JPH11513522A5 (cg-RX-API-DMAC7.html)
JP2000500361A5 (cg-RX-API-DMAC7.html)
JP2000500115A5 (cg-RX-API-DMAC7.html)
JP2000500342A5 (cg-RX-API-DMAC7.html)
JP2000500192A5 (cg-RX-API-DMAC7.html)
JP2000504210A5 (cg-RX-API-DMAC7.html)
JP2000500112A5 (cg-RX-API-DMAC7.html)
JP2000500051A5 (cg-RX-API-DMAC7.html)
JP2000500397A5 (cg-RX-API-DMAC7.html)
JP2000500407A5 (cg-RX-API-DMAC7.html)
JP2000500019A5 (cg-RX-API-DMAC7.html)
JP2000500166A5 (cg-RX-API-DMAC7.html)
JP2000500125A5 (cg-RX-API-DMAC7.html)
JP2000501233A5 (cg-RX-API-DMAC7.html)
JP2000500346A5 (cg-RX-API-DMAC7.html)
JP2000500044A5 (cg-RX-API-DMAC7.html)
JP2000500090A5 (cg-RX-API-DMAC7.html)
JPH10509740A5 (cg-RX-API-DMAC7.html)